|
Bifidobacterium animalis subsp. lactis HN019
- HN019 has been studied for supporting gut motility and regularity — for example, shortened colonic transit time and increased bowel-movement frequency in adults with functional constipation.
- Helps maintain a healthy intestinal microbiota, especially in aging populations, and competes with potentially harmful microbes.
- Shows immune‐modulating effects: reducing pro-inflammatory markers and modulating oral/periodontal immune responses.
- WebMD summarizes that B. lactis (which includes B. animalis subsp. lactis) helps break down food, absorb nutrients, and fight off harmful organisms.
- Practical implication: For those with bowel irregularity or looking to support healthy gut ecology (especially older adults), HN019 has strong clinical support.
Bifidobacterium animalis subsp. lactis B420
- Extensively studied for metabolic health and weight management.
- Human trials show reduced body fat mass, waist circumference, and energy intake when B420 was used (with or without prebiotic fiber).
- Improves intestinal epithelial integrity (gut barrier), modulates microbiota composition, supports SCFA production, and may reduce inflammation via lower endotoxemia.
- Shown to increase abundance of Akkermansia muciniphila, associated with healthier metabolism.
- Practical implication: Relevant for metabolic support (weight, waist size, gut-barrier function).
Lactobacillus rhamnosus GG (LGG)
- One of the most studied probiotic strains; proven benefits for digestive health.
- Reduces duration of acute diarrhoea and prevents antibiotic-associated diarrhoea.
- Supports gut barrier function (tight junctions, mucosal healing) and immune balance.
- Emerging evidence suggests potential gut–brain axis benefits (mood, cognition).
- Practical implication: A solid “foundation” probiotic for general gut health and microbiome recovery post-antibiotics or illness.
|
Akkermansia muciniphila AH39
- A next-generation probiotic linked to metabolic health, insulin sensitivity, and gut-barrier integrity.
- Acts on the gut mucus layer, improving barrier function and reducing endotoxemia (a driver of inflammation).
- Strain AH39 specifically shown to modulate regulatory T cell (Treg) populations, influencing immune balance.
- Practical implication: Relevant for metabolic health, gut-barrier repair, and systemic inflammation — though human data is still limited.
Clostridium butyricum
- A butyrate-producing gut symbiont. Butyrate fuels colon cells, supports gut barrier, and reduces inflammation.
- Shown to improve immunity (increases IgA/IgM), inhibit pathogens, and correct microbiota imbalances.
- Animal studies show improved metabolic outcomes (obesity, liver inflammation) through microbiota modulation.
- Practical implication: Excellent for supporting gut ecosystem balance and SCFA (butyrate) production for gut, immune, and gut–brain axis health.
|